The 2017 Nobel Prize in physiology or medicine was awarded on Monday morning to Jeffrey Hall, Michael Rosbash, and Michael Young for their discoveries of the molecular underpinnings of the circadian rhythms that help organisms adapt to our 24-hour days.

The scientists “were able to peek inside our biological clock and elucidate its inner workings,” said Thomas Perlmann, secretary of the Nobel Committee for Physiology or Medicine, who announced the prize in Stockholm. “Their discoveries explain how plants, animals, and humans adapt their biological rhythm so that it is synchronized with the Earth’s revolutions.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • on a serious note, does this biological clock show any difference due to food availability in the environment, lenght of day in the extreme like 6 months of night, temperature of the day and night, social and cultural rituals and health of the individual and the behavior of the natural predators, like animal or human, of the individual. I do congratulate the reasearchers on their prize and their good work. Now the work can start on what the trigger for the change is.

  • This research has not been lost on pharma, for example certain chemotherapies are best administered at certain times of the day. Working with researchers at Medical College of Virginia, about 15 years ago my company launched a novel formulation of propranolol called Innopran XL. The drug attacks the problem of the early morning rise in blood pressure that is associated with stroke and heart attack. Innopran XL is a delayed release formulation, which when administered at bedtime begins releasing the drug 4-5 hours later, with propranol concentrations peaking in late morning, thereby attenuating the circadian rise in BP associated with the above complications.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy